Medicine
Beizray kit
Beizray kit is a prescription medicine containing Docetaxel, marketed by Zydus Lifesciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Protect from freezing. Store at 20°C to 25°C (68°F to 77°F). Excursions…
Key facts
- Active ingredient (INN)
- Docetaxel
- Brand
- Beizray
- Dosage form
- Kit
- Packs
- 1 kit
- Marketing authorisation holder
- Zydus Lifesciences
- Manufacturer
- Zydus LifesciencesIndia
- Origin register
- US FDA, United States
- Storage
- Protect from freezing. Store at 20°C to 25°C (68°F to 77°F). Excursions permitted from 15°C to 30°C (59°F to 86°F). Retain in the original package to protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01CD02 Docetaxel
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 August 2025
- Identifiers
- RxCUI 1860480, 1860485, 2054168 +7DailyMed set ID 8fb7d980-d6c7-468b-a9f0-adff16101a4bNDC 70710-2091, 70710-2093Application NDA218711
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 kit * 4 mL in 1 vial, glass * 50 mL in 1 vial, glass | 70710-2091-3 | Zydus LifesciencesIndia | 28 August 2025 |
| 1 kit in 1 kit * 4 mL in 1 vial, glass * 50 mL in 1 vial, glass * 4 mL in 1 vial, glass | 70710-2093-4 | Zydus LifesciencesIndia | 28 August 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Docetaxel
Clinical summary
Docetaxel is a microtubule inhibitor indicated for breast Cancer (BC), among other approved uses. It is available as injection and kits for intravenous use. MedsAcross supplies Docetaxel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DocetaxelFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Docetaxel prescribing information (Sanofi-Aventis) · U.S. National Library of Medicine, DailyMed
- Taxotere: European public assessment report (EPAR) · European Medicines Agency
- Docetaxel Accord: European public assessment report (EPAR) · European Medicines Agency
Need Beizray kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.